Praxis Precision Medicines, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Praxis Precision Medicines, Inc. (PRAX) holds an ST Score of 62.9 out of 100 (B), with its strongest factor being Financial Strength (A+) and its weakest Momentum (B-). Analysts rate PRAX Buy across 18 ratings with a $603.83 average price target (+1.0% vs the current $300.65).
- Strongest
- Financial StrengthA+
- Weakest
- MomentumB-
All factor grades
- Financial StrengthA+
- ForecastA-
- ProfitabilityB+
- GrowthB
- ValuationB-
- MomentumB-
- Piotroski2/9
Contact
PRAX stock: frequently asked questions
What is PRAX's ST Score?
Praxis Precision Medicines, Inc. (PRAX) has an ST Score of 62.9 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PRAX a buy, sell, or hold?
Wall Street's consensus rating on PRAX is Buy based on 18 analyst ratings. Our own ST Score grades it B (62.9/100). This is data, not investment advice — always do your own research.
What is PRAX's valuation grade?
Praxis Precision Medicines, Inc. (PRAX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PRAX's growth grade?
Praxis Precision Medicines, Inc. (PRAX) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PRAX's profitability grade?
Praxis Precision Medicines, Inc. (PRAX) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PRAX's financial strength grade?
Praxis Precision Medicines, Inc. (PRAX) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PRAX?
The average analyst price target for Praxis Precision Medicines, Inc. (PRAX) is $603.83 from 18 analysts, which is +1.0% versus the recent price of $300.65.
What is PRAX's Piotroski score?
Praxis Precision Medicines, Inc. (PRAX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.